Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
Hansen K, Kumar S, Logronio K, Whelan S, Qurashi S, Cheng HY, Drake A, Tang M, Wall P, Bernados D, Leung L, Ophir E, Alteber Z, Cojocaru G, Galperin M, Frenkel M, White M, Hunter J, Liang SC, Kotturi MF. Hansen K, et al. Among authors: leung l. Cancer Immunol Immunother. 2021 Dec;70(12):3525-3540. doi: 10.1007/s00262-021-02921-8. Epub 2021 Apr 26. Cancer Immunol Immunother. 2021. PMID: 33903974 Free PMC article.
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function.
Whelan S, Ophir E, Kotturi MF, Levy O, Ganguly S, Leung L, Vaknin I, Kumar S, Dassa L, Hansen K, Bernados D, Murter B, Soni A, Taube JM, Fader AN, Wang TL, Shih IM, White M, Pardoll DM, Liang SC. Whelan S, et al. Among authors: leung l. Cancer Immunol Res. 2019 Feb;7(2):257-268. doi: 10.1158/2326-6066.CIR-18-0442. Epub 2019 Jan 18. Cancer Immunol Res. 2019. PMID: 30659054 Free PMC article.
ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses.
Hecht I, Toporik A, Podojil JR, Vaknin I, Cojocaru G, Oren A, Aizman E, Liang SC, Leung L, Dicken Y, Novik A, Marbach-Bar N, Elmesmari A, Tange C, Gilmour A, McIntyre D, Kurowska-Stolarska M, McNamee K, Leitner J, Greenwald S, Dassa L, Levine Z, Steinberger P, Williams RO, Miller SD, McInnes IB, Neria E, Rotman G. Hecht I, et al. Among authors: leung l. J Immunol. 2018 Mar 15;200(6):2025-2037. doi: 10.4049/jimmunol.1700325. Epub 2018 Feb 5. J Immunol. 2018. PMID: 29431694 Free PMC article.
CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.
Cao ZA, Bass KE, Balasubramanian S, Liu L, Schultz B, Verner E, Dai Y, Molina RA, Davis JR, Misialek S, Sendzik M, Orr CJ, Leung L, Callan O, Young P, Dalrymple SA, Buggy JJ. Cao ZA, et al. Among authors: leung l. Mol Cancer Ther. 2006 Jul;5(7):1693-701. doi: 10.1158/1535-7163.MCT-06-0042. Mol Cancer Ther. 2006. PMID: 16891455
1,373 results